报价延迟最少15分钟:2026/02/15 14:53 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.2 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.06/--
|
|
企业价值
1.11B
|
| 资产负债 |
|
每股账面净值
0.63
|
| 现金流量 |
|
现金流量率
0.00
|
| 损益表 |
|
收益
4.43M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions. |
